Targeting T cells to treat atherosclerosis: odyssey from bench to bedside

Jessica Bullenkamp, Sip Dinkla, Juan Carlos Kaski, Ingrid Dumitriu

Research output: Contribution to journalReview articlepeer-review

19 Citations (Scopus)


More than 150 years from the initial description of inflammation in atherosclerotic plaques, randomized clinical trials to test anti-inflammatory therapies in atherosclerosis have recently been initiated. Lymphocytes and macrophages are main participants in the inflammatory response in atherosclerosis. T lymphocytes operate mainly by exerting strong influences on the function of many cells in the immune system and beyond, and co-ordinating their interactions. Importantly, T lymphocytes are not a homogenous population, but include several subsets with specialized functions that can either promote or suppress inflammation. The interactions between these T-lymphocyte subsets have critical consequences on the course and outcome of inflammation. The complexity of the inflammatory response in atherosclerosis poses significant challenges on translating experimental findings into clinical therapies and makes the journey from bench to bedside an arduous one. Here, we summarize recent advances on the role of CD4(+) T cells in the inflammatory process in atherosclerosis and discuss potential therapies to modulate these lymphocytes that may provide future breakthroughs in the treatment of atherosclerosis.

Original languageEnglish
Pages (from-to)194-9
Number of pages6
JournalEuropean heart journal. Cardiovascular pharmacotherapy
Issue number3
Publication statusPublished - Jul 2016


  • Animals
  • Atherosclerosis/blood
  • CD4-Positive T-Lymphocytes/drug effects
  • Humans
  • T-Lymphocytes/drug effects
  • T-Lymphocytes, Regulatory/drug effects


Dive into the research topics of 'Targeting T cells to treat atherosclerosis: odyssey from bench to bedside'. Together they form a unique fingerprint.

Cite this